Targovax ASA: second quarter and first half 2020 results
Oslo, Norway, 20 August 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its second quarter and first half 2020 results. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today (details below). HIGHLIGHTS FOR THE SECOND QUARTER AND FIRST HALF 2020 Data · Announced encouraging clinical and immune data in mesothelioma combining ONCOS-102 and chemotherapy demonstrating that ONCOS-102 activates patients’ immune